This anti GST-Eu cryptate is used in the HTRF® Kinase Binding format in combination with a GST-tagged Kinase and red-fluorescent tracers.
Feature | Specification |
---|---|
Application | Biochemical Enzymatic Assay |
Sample Volume | 5 µL |
This anti GST-Eu cryptate is used in the HTRF® Kinase Binding format in combination with a GST-tagged Kinase and red-fluorescent tracers.
MAb Anti GST-Eu cryptate Kinase Binding is an IgG2a raised against Glutathione S-transferase, labeled with Eu. It has been shown to react with GST-tagged kinases.
This reagent is intended for use in the biochemical HTRF Kinase Binding platform.
Application |
Biochemical Enzymatic Assay
|
---|---|
Brand |
HTRF
|
Detection Modality |
HTRF
|
Product Group |
Fluorescent Reagent
|
Sample Volume |
5 µL
|
Shipping Conditions |
Shipped in Dry Ice
|
Target Class |
Kinases
|
Technology |
TR-FRET
|
Therapeutic Area |
Metabolism/Diabetes
Neuroscience
Oncology & Inflammation
|
Unit Size |
1,000 assay points
|
The binding of the tracers is detected in a sandwich assay format using the Anti GST antibody labeled with Europium Cryptate (donor), which binds to the GST-tagged Kinase, and a red fluorescent tracer labelled with d2 (acceptor). The detection principle is based on HTRF® technology. The HTRF ratio (665/620) will increase upon the addition of more of the tracer, and will saturate depending on the dissociation constant (Kd) of the tracer to the GST-tagged kinase.
Saturation binding experiments on the three tracers (i.e. Staurosporine-Red, Dasatinib-Red, and Sunitinib-Red) can be run in 96- or 384-well plates (20 µL final volume). First, a dilution series of tracer ranging between 0 and 1 µM in the Kinase Binding Buffer is prepared in a 96-well non-binding plate. Next, 5 µL of Kinase Binding Buffer are dispensed into the final 96- or 384-well plate. Then 5 µL of GST tagged-Kinase are added, followed by 5 µL of Anti-GST Eu-cryptate. Finally, 5 µL of the red tracer solution are added. The HTRF ratio is measured after 1 H of incubation.
The binding of the tracers is detected in a sandwich assay format using the Anti-GST labeled with Europium Cryptate (donor), which binds to the tagged Kinase, and a red fluorescent tracer labelled with d2 (acceptor). The detection principle is based on HTRF® technology. The HTRF ratio (665/620) will increase upon the addition of more of the tracer, and will saturate depending on the dissociation constant (Kd ) of the tracer to the tagged kinase. When an inhibitor of the kinase is added, the tracer will be displaced and the HTRF signal will disappear, depending on the dose.
Pharmacological evaluation of inhibitors of interest can be run in 96- or 384-well plates. First, a dilution series of inhibitor ranging between 40 µM and 0.23 nM is prepared, and 5 µL of each concentration are dispensed into the plate. Next, 5 µL of tagged-Kinase are added, followed by 5 µL of anti-GST Eu-cryptate. Finally, 5 µL of tracer solution are added, prepared at 4x the final concentration. The HTRF ratio is measured after 1H of incubation. Analyses of the data give typical dose response curves ranging between 10 µM and 56 pM, enabling an evaluation of the IC50/Ki values for the inhibitor of interest.
A typical saturation binding experiment is performed using final tracer concentrations between 0 and 250 nM, and measuring total- and non-specific binding signals. Subtracting the non-specific from the total binding signal gives the specific signal, which can be analysed to give the Kd. Here an example is shown where the best tracer for inhibitor studies proved to be Staurosporine-Red, with a Kd of 43 nM on 5 nM SRC-GST.
Dose response curves of various known kinase inhibitors (Staurosporine, Dasatinib, PP2, Imatinib, Tozasertib, Sunitinib, Gefitinib, and Sorafenib) were measured using Staurosporine-Red at its Kd (29 nM) on 5 nM FGFR1-GST. Staurosporine has an inihibition constant of 13 nM, in correlation with the literature value of 9.1 nM. Imatinib and Gefinitib do not compete, as can be expected for FGFR1.
Are you looking for resources, click on the resource type to explore further.
A Bruton Tyrosine Kinase (BTK) case study
PROteolysis Targeting Chimeras (PROTACs) are one of the latest trending tools used in...
Discover the versatility and precision of Homogeneous Time-Resolved Fluorescence (HTRF) technology. Our HTRF portfolio offers a...
Challenge kinase binding assays and win with HTRF™ technology
The 3 application notes present a new HTRF kinase binding assay that...
Challenge kinase binding assays and win with HTRF™ technology
The 3 application notes present a new HTRF kinase binding assay that...
Challenge kinase binding assays and win with HTRF™ technology
The 3 application notes present a new HTRF kinase binding assay that...
This guide provides you an overview of HTRF applications in several therapeutic areas.
We are here to answer your questions.